Table 4 Characteristics of patients with stage II pure mucinous carcinoma of the breast
Endocrine therapy | P | |||
|---|---|---|---|---|
With chemotherapy (n = 30) | Without chemotherapy (n = 15) | |||
Age, years | 0.001 | |||
mean (SD) | 43.43 (6.17) | 61.16 (16.89) | ||
median | 44.68 | 64.20 | ||
range | 31.0, 57.0 | 28.0, 84.0 | ||
Tumor size, cm | 0.772 | |||
mean (SD) | 3.60 (2.89) | 3.34 (2.43) | ||
median | 3.0 | 2.8 | ||
range | 0.20, 17.0 | 2.0, 12.0 | ||
Tumor stage, n (%), | 0.545 | |||
T1 | 2 (7.14) | 0 (0) | ||
T2 | 26 (92.86) | 14 (100) | ||
unknown or other | 2 | 1 | ||
Grade, n (%), | 1.000 | |||
I | 9 (81.82) | 3 (75) | ||
II | 2 (18.18) | 1 (25) | ||
unknown or other | 19 | 11 | ||
Lymphovascular invasion, n (%), | 0.624 | |||
present | 4 (21.05) | 1 (8.33) | ||
absent | 15 (78.95) | 11 (91.67) | ||
unknown or other | 11 | 3 | ||
ER status, n (%), | 1.000 | |||
positive | 28 (93.33) | 14 (93.33) | ||
negative | 2 (6.67) | 1 (6.67) | ||
PR status, n (%), | 0.695 | |||
positive | 23 (76.67) | 13 (86.67) | ||
negative | 7 (23.33) | 2 (13.33) | ||
HER2 status, n (%), | 1.000 | |||
positive | 1 (3.70) | 1 (7.14) | ||
negative | 26 (96.30) | 13 (92.86) | ||
unknown or other | 3 | 1 | ||
Lymph node status (%) | 0.396 | |||
positive | 6 (20) | 1 (6.67) | ||
negative | 24 (80) | 14 (93.33) | ||
Primary treatment, n (%), | 1.000 | |||
mastectomy | 23 (76.67) | 11 (73.33) | ||
lumpectomy with RT | 7 (23.33) | 4 (26.67) | ||
Follow up time, months | ||||
median | 57 | 43 | ||
range | 3, 139 | 12, 86 | ||
10-year disease-free survival | 87.69% | 75% | 0.637 | |
10-year overall survival rate | 88.44% | 100% | 0.424 | |